Metabolic Heterogeneity of Brain Tumor Cells of Proneural and Mesenchymal Origin

Seliger C, Meyer AL, Leidgens V, Rauer L, Moeckel S, Jachnik B, Proske J, Dettmer K, Rothhammer-Hampl T, Kaulen LD, Riemenschneider MJ, Oefner PJ, Kreutz M, Schmidt NO, Merrill M, Uhl M, Renner K, Vollmann-Zwerenz A, Proescholdt M, Hau P (2022)


Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 23

Article Number: 11629

Journal Issue: 19

DOI: 10.3390/ijms231911629

Abstract

Brain-tumor-initiating cells (BTICs) of proneural and mesenchymal origin contribute to the highly malignant phenotype of glioblastoma (GB) and resistance to current therapies. BTICs of different subtypes were challenged with oxidative phosphorylation (OXPHOS) inhibition with metformin to assess the differential effects of metabolic intervention on key resistance features. Whereas mesenchymal BTICs varied according to their invasiveness, they were in general more glycolytic and less responsive to metformin. Proneural BTICs were less invasive, catabolized glucose more via the pentose phosphate pathway, and responded better to metformin. Targeting glycolysis may be a promising approach to inhibit tumor cells of mesenchymal origin, whereas proneural cells are more responsive to OXPHOS inhibition. Future clinical trials exploring metabolic interventions should account for metabolic heterogeneity of brain tumors.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Seliger, C., Meyer, A.-L., Leidgens, V., Rauer, L., Moeckel, S., Jachnik, B.,... Hau, P. (2022). Metabolic Heterogeneity of Brain Tumor Cells of Proneural and Mesenchymal Origin. International Journal of Molecular Sciences, 23(19). https://doi.org/10.3390/ijms231911629

MLA:

Seliger, Corinna, et al. "Metabolic Heterogeneity of Brain Tumor Cells of Proneural and Mesenchymal Origin." International Journal of Molecular Sciences 23.19 (2022).

BibTeX: Download